Hierarchical multi-omics data integration and modeling predict cell-specific chemical proteomics and drug responses

Cell Rep Methods. 2023 Apr 17;3(4):100452. doi: 10.1016/j.crmeth.2023.100452. eCollection 2023 Apr 24.

Abstract

Drug-induced phenotypes result from biomolecular interactions across various levels of a biological system. Characterization of pharmacological actions therefore requires integration of multi-omics data. Proteomics profiles, which may more directly reflect disease mechanisms and biomarkers than transcriptomics, have not been widely exploited due to data scarcity and frequent missing values. A computational method for inferring drug-induced proteome patterns would therefore enable progress in systems pharmacology. To predict the proteome profiles and corresponding phenotypes of an uncharacterized cell or tissue type that has been disturbed by an uncharacterized chemical, we developed an end-to-end deep learning framework: TransPro. TransPro hierarchically integrated multi-omics data, in line with the central dogma of molecular biology. Our in-depth assessments of TransPro's predictions of anti-cancer drug sensitivity and drug adverse reactions reveal that TransPro's accuracy is on par with that of experimental data. Hence, TransPro may facilitate the imputation of proteomics data and compound screening in systems pharmacology.

Keywords: chemical proteomics; deep learning; drug discovery; drug efficacy prediction; machine learning; multi-task learning; phenotype screening; precision medicine; side effect prediction; systems pharmacology.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Molecular Biology
  • Multiomics
  • Proteome
  • Proteomics*

Substances

  • Proteome